Weekly low-dose @entity1205 in advanced XXXX previously treated with two chemotherapy regimens.

@entity1 @entity1149 @entity1205 @entity3907
BACKGROUND: The role of salvage chemotherapy in advanced @entity1149 ( @entity1149 ) is still controversial, but the recent development of a number of active antineoplastic agents has created new possibilities for disease management. The aim of this study was to evaluate the activity and safety of weekly @entity1205 treatment in @entity1 with advanced @entity1149 previously treated with two chemotherapy regimens. @entity1 AND METHODS: The study involved 26 @entity1 with histologically documented stage IIIB, IV or recurrent metastatic @entity1149 previously treated with two non- @entity3907 based-chemotherapy regimens. They all received @entity1205 25 mg/m(2)/week administered as a 1-h infusion in an outpatient setting with corticosteroid premedication. RESULTS: Fourteen of the 26 @entity1 (54%) had distant metastases and 12 (46%) chest-localised disease. Six @entity1 (23%; confidence interval: 9.8-44.1%) showed a partial response, 8 (31%) stable disease, and 12 (46%) progressive disease. The median time to progression was 4 months (range 2-8), and the median survival was 7+ months (range 3-13+). There were no statistically significant differences between the global quality of life scores recorded at baseline and those recorded after subsequent cycles. The treatment was very well tolerated. CONCLUSION: The results of this study suggest that weekly low-dose @entity1205 is effective, well tolerated and maintains a relatively good quality of life in @entity1 with advanced @entity1149 previously exposed to two chemotherapy regimens.
